With in-vivo CAR-T therapies gaining global momentum, a new whitepaper from Novotech, a leading global full-service clinical ...

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in ...

Shahzad Raza, MD, discusses the phase 2 RedirecTT-1 study which investigated the combination of talquetamab and teclistamab for treating patients with relapsed/refractory multiple myeloma complicated ...

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T ...

The patients receiving AHSCT had 5-year LFS of 46.3% and OS of 53.3%, which were better outcomes than those of the MRC UKALL XII/ECOG E2993 trial conducted from 2006 to 2010.

Prof. LIANG Xingjie's team from the National Center for Nanoscience and Technology, along with Prof. GONG Ningqiang from the University of Science and Technology of China, has developed a biomimetic ...

Ryan Richardson joined BioNTech in 2018 and has served as Chief Strategy Officer since January 2020. During his time at the Company, he contributed significantly to BioNTech’s successful development, ...

Chimeric antigen receptor (CAR) T-cell immunotherapy was reported by ASCO in 2018 as the advance of the year. This innovative cancer treatment originated from intensive experimental work in academic ...

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and ...

Dr. Olalekan O. Oluwole explained how CAR T is used to treat high-risk blood cancers and highlighted the potential of ...

RNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers tracked the in situ CAR-T cells to assess their effectiveness and safety.